🇺🇸 FDA
Pipeline program

Libmeldy 2-10 x 10^6 cells/mL dispersion for infusion

OTL-200-07

Phase 3 small_molecule active

Quick answer

Libmeldy 2-10 x 10^6 cells/mL dispersion for infusion for Metachromatic Leukodystrophy (MLD) is an autosomal recessive disorder caused by mutations is a Phase 3 program (small_molecule) at Orchard Therapeutics (Netherlands) B.V. with 1 ClinicalTrials.gov record(s).

Program details

Company
Orchard Therapeutics (Netherlands) B.V.
Indication
Metachromatic Leukodystrophy (MLD) is an autosomal recessive disorder caused by mutations
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials